Laul.Ns
Lupin Limited is a pharmaceutical company that develops, manufactures, and markets generic and branded formulations of APIs, finished dosage forms, and biologics.
Business. Lupin Limited is a pharmaceutical company that develops, manufactures, and markets generic and branded formulations of APIs, finished dosage forms, and biologics.
Analyst recommendations
14 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Lupin Limited is a pharmaceutical company that develops, manufactures, and markets generic and branded formulations of APIs, finished dosage forms, and biologics.
Lupin Limited has a debt-to-equity ratio of 0.48, indicating a relatively conservative capital structure. The company's liquidity is assessed as medium, with a current ratio of 1.33, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk.
In terms of profitability, Lupin Limited has a return on equity (ROE) of 16.77% and a return on assets (ROA) of 8.46%. These figures are strong and suggest the company is effectively utilizing its equity and assets to generate profits. The company's operating income of 12,976.6 million INR and net income of 8,887.9 million INR further support its profitability.
Lupin Limited's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification disclosed. The company's revenue of 68,129.0 million INR is derived from its core pharmaceutical business, with no material exposure to other segments or regions.
The company's growth trajectory is positive, with a strong operating cash flow of 16,235.0 million INR and a free cash flow of 2,136.2 million INR. These figures indicate that the company is generating sufficient cash to fund its operations and potentially invest in growth opportunities. The capital expenditure of -10,699.5 million INR suggests the company is investing in its infrastructure and capabilities.
Lupin Limited faces a medium liquidity risk, as noted in the risk assessment. The company's dilution risk is assessed as low, with no significant dilution potential identified. The company's capital structure and financial position suggest it is not currently under pressure to issue additional shares to meet its financial obligations.
Recent events and filings indicate that Lupin Limited is maintaining a strong financial position. The company's financial snapshot and valuation metrics suggest it is well-positioned to continue its operations and growth initiatives. Analyst estimates provide a range of price targets, with a mean of 1,022.69 INR and a median of 1,045.00 INR, indicating a generally positive outlook from the investment community.
- Lupin Limited has a strong return on equity (16.77%) and return on assets (8.46%), indicating effective use of equity and assets to generate profits.
- The company's debt-to-equity ratio of 0.48 suggests a conservative capital structure, reducing financial risk.
- Lupin Limited's liquidity is assessed as medium, with a current ratio of 1.33, indicating it has sufficient short-term assets to cover its short-term liabilities.
- The company's operating cash flow of 16,235.0 million INR and free cash flow of 2,136.2 million INR support its financial stability and growth potential.
- Analysts have a generally positive outlook, with a mean price target of 1,022.69 INR and a median price target of 1,045.00 INR.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 19,46 |
| Revenue | —no estimate | —no estimate | 78,6B INR |
| Operating income | —no estimate | —no estimate | 15,4B INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- LAUL.NS Market data — financials · 2026-05-28
- Laurus Labs Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Satyanarayana ChavaChief Executive Officer, Executive Director